MeiraGTx

MGTXPhase 2

MeiraGTx is focused on advancing a pipeline of gene therapies for serious conditions with high unmet medical need, primarily in ophthalmology and neurology. The company's core strength lies in its integrated platform encompassing vector design, promoter engineering, and manufacturing capabilities. Key strategic partnerships, including a significant collaboration with Janssen Pharmaceuticals, provide validation and resources for its lead programs. The company is navigating the complex clinical and regulatory pathway typical of gene therapy developers.

Market Cap

$579.5M

Employees

100-250

Focus

Biotech

MGTX · Stock Price

USD 7.206.45 (-47.25%)

Historical price data

AI Company Overview

Technology Platform

Proprietary AAV vector engineering and gene regulation platform featuring tissue-specific and inducible promoters, optimized capsids, and integrated cGMP manufacturing capabilities.

Pipeline Snapshot

7 drugs in pipeline

Drug	Indication	Stage
AAV - CNGB3	Achromatopsia	Phase 1/2
adeno-associated virus vector AAV- CNGA3	Achromatopsia	Phase 1/2
AAV RPE65	Leber Congenital Amaurosis	Phase 1/2
AAV2hAQP1	Squamous Cell Head and Neck Cancer	Phase 1
AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (bo...	Radiation-Induced Parotid Gland Hypofunction	Phase 1

Funding History

Total raised: $120M

IPO$75MUndisclosedJan 1, 2018

Series B$45MJeito CapitalJan 1, 2017

Opportunities

Potential first approval and commercialization of bota-vec for XLRP, representing a blockbuster opportunity in a rare disease with no approved therapies.

Expansion of the platform into additional ophthalmic and neurological indications.

Leveraging the Janssen partnership for global development and commercial scale.

Risk Factors

High risk of clinical trial failure or disappointing data readouts.

Significant regulatory hurdles for gene therapy approval and potential safety concerns.

Heavy reliance on the success of the Janssen partnership and future capital raises to fund operations.

Competitive Landscape

Faces competition from other gene therapy leaders like Spark/Roche in ophthalmology and numerous biopharma players in neurology. Differentiation is based on proprietary vector/promoter technology and integrated manufacturing, but clinical efficacy data will be the ultimate determinant of competitive position.

Publications

Pipeline